Drug Trial Radar · NCT04469465
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Dec 16, 2020
Primary completion
Jun 29, 2022
Study completion Jan 16, 2024
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
DanicopanDrug
Oral tablet
PlaceboDrug
Oral tablet
C5 InhibitorDrug
Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hgb at Week 12Time frame: Baseline, Week 12
Locations
62 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Weston, Florida
Research Site
Chicago, Illinois
Research Site
Kalamazoo, Michigan
Research Site
New York, New York
Research Site
Dallas, Texas
Research Site
Milwaukee, Wisconsin
Research Site
Belém, Brazil
Research Site
Curitiba, Brazil
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de de Janeiro, Brazil
Research Site
Toronto, Ontario, Canada
Research Site
Brno, Czechia
Research Site
Lille, France
Research Site
Paris, France
Research Site
Pessac, France
Research Site
Pierre-Bénite, France
Research Site
Ulm, Germany
Research Site
Athens, Greece
Research Site
Thessaloniki, Greece
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Avellino, Italy
Research Site
Bassano del Grappa, Italy
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Reggio Calabria, Italy
Research Site
Roma, Italy
Research Site
Bunkyō City, Japan
Research Site
Fukuoka, Japan
Research Site
Kashiwa-shi, Japan
Research Site
Kyoto, Japan
Research Site
Nagakute-shi, Japan
Research Site
Ogaki-shi, Japan
Research Site
Osaka, Japan
Research Site
Sayama, Japan
Research Site
Shibuya-ku, Japan
Research Site
Tanabe-shi, Japan
Research Site
Toyoake-shi, Japan
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.